Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations.
10.3779/j.issn.1009-3419.2022.102.34
- Author:
Guowei ZHANG
1
;
Ruirui CHENG
2
;
Yuanyuan NIU
1
;
Huijuan WANG
1
;
Xiangtao YAN
1
;
Mina ZHANG
1
;
Xiaojuan ZHANG
1
;
Jinpo YANG
1
;
Chunhua WEI
1
;
Zhiyong MA
1
Author Information
1. Department of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
2. Department of Respiratory Medicine,
The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Concomitant genetic alteration;
EGFR mutation;
Lung neoplasms;
Targeted therapy
- MeSH:
Adenocarcinoma of Lung/genetics*;
ErbB Receptors/genetics*;
Humans;
Lung Neoplasms/pathology*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*;
Retrospective Studies
- From:
Chinese Journal of Lung Cancer
2022;25(9):651-657
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Epidermal growth factor receptor (EGFR) mutations are often associated with non-EGFR genetic alterations, which may be a reason for the poor efficacy of EGFR tyrosine kinase inhibitors (TKIs). Here we conducted this study to explore whether EGFR-TKIs combined with chemotherapy would benefit advanced lung adenocarcinoma patients with both sensitive EGFR mutation and concomitant non-EGFR genetic alterations.
METHODS:Cases of advanced lung adenocarcinoma with EGFR mutation combined with concomitant non-EGFR genetic alterations were retrospectively collected. And the patients were required to receive first-line EGFR-TKIs and chemotherapy combination or EGFR-TKIs monotherapy. Demographic, clinical and pathological data were collected, and the electronic imaging data were retrieved to evaluate the efficacy and time of disease progression. Survival data were obtained through face-to-face or telephone follow-up. The differences between the two groups in objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were investigated.
RESULTS:107 patients were included, including 63 cases in the combination group and 44 cases in the monotherapy group. The ORR were 78% and 50% (P=0.003), and DCR were 97% and 77% (P=0.002), respectively. At a median follow-up of 13.7 mon, a PFS event occurred in 38.1% and 81.8% of patients in the two groups, with median PFS of 18.8 mon and 5.3 mon, respectively (P<0.000,1). Median OS was unreached in the combination group, and 27.8 mon in the monotherapy group (P=0.31). According to the Cox multivariate regression analysis, combination therapy was an independent prognostic factor of PFS CONCLUSIONS: In patients with EGFR-mutant advanced lung adenocarcinoma with concomitant non-EGFR genetic alterations, combination of TKIs and chemotherapy was significantly superior to EGFR-TKIs monotherapy, which should be the preferred treatment option.
